share_log

CSPC Pharmaceutical Group Limited's (HKG:1093) Largest Shareholders Are Individual Investors With 39% Ownership, Institutions Own 31%

CSPC Pharmaceutical Group Limited's (HKG:1093) Largest Shareholders Are Individual Investors With 39% Ownership, Institutions Own 31%

石药集团有限公司(HKG: 1093)的最大股东是个人投资者,拥有39%的所有权,机构拥有31%
Simply Wall St ·  05/06 18:41

Key Insights

关键见解

  • The considerable ownership by individual investors in CSPC Pharmaceutical Group indicates that they collectively have a greater say in management and business strategy
  • A total of 10 investors have a majority stake in the company with 50% ownership
  • Insider ownership in CSPC Pharmaceutical Group is 24%
  • 个人投资者对CSPC制药集团的大量所有权表明,他们在管理和业务战略中集体拥有更大的发言权
  • 共有10名投资者持有该公司的多数股权,所有权为50%
  • CSPC制药集团的内部所有权为24%

Every investor in CSPC Pharmaceutical Group Limited (HKG:1093) should be aware of the most powerful shareholder groups. We can see that individual investors own the lion's share in the company with 39% ownership. In other words, the group stands to gain the most (or lose the most) from their investment into the company.

石药集团有限公司(HKG: 1093)的每位投资者都应了解最强大的股东群体。我们可以看到,个人投资者拥有公司的大部分股份,所有权为39%。换句话说,该集团将从对公司的投资中获得最多(或损失最大)。

And institutions on the other hand have a 31% ownership in the company. Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders.

另一方面,机构拥有该公司31%的所有权。内部人士通常拥有很大一部分年轻、规模较小的公司,而大公司则往往将机构作为股东。

In the chart below, we zoom in on the different ownership groups of CSPC Pharmaceutical Group.

在下图中,我们放大了CSPC制药集团的不同所有权群体。

ownership-breakdown
SEHK:1093 Ownership Breakdown May 6th 2024
SEHK: 1093 所有权明细 2024 年 5 月 6 日

What Does The Institutional Ownership Tell Us About CSPC Pharmaceutical Group?

关于CSPC制药集团,机构所有权告诉我们什么?

Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.

机构在向自己的投资者报告时通常会根据基准来衡量自己,因此,一旦股票被纳入主要指数,他们通常会对股票更加热情。我们预计大多数公司都会有一些机构在册,尤其是在它们正在成长的情况下。

As you can see, institutional investors have a fair amount of stake in CSPC Pharmaceutical Group. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at CSPC Pharmaceutical Group's earnings history below. Of course, the future is what really matters.

如您所见,机构投资者持有CSPC制药集团的大量股份。这表明专业投资者有一定的信誉。但是我们不能仅仅依靠这个事实,因为机构有时会像所有人一样进行不良投资。如果多家机构同时改变对股票的看法,你可能会看到股价快速下跌。因此,值得在下面查看CSPC制药集团的收益记录。当然,未来才是真正重要的。

earnings-and-revenue-growth
SEHK:1093 Earnings and Revenue Growth May 6th 2024
SEHK: 1093 收益及收入增长 2024 年 5 月 6 日

We note that hedge funds don't have a meaningful investment in CSPC Pharmaceutical Group. Our data suggests that Dongchen Cai, who is also the company's Top Key Executive, holds the most number of shares at 24%. When an insider holds a sizeable amount of a company's stock, investors consider it as a positive sign because it suggests that insiders are willing to have their wealth tied up in the future of the company. In comparison, the second and third largest shareholders hold about 6.3% and 6.2% of the stock.

我们注意到,对冲基金没有对CSPC制药集团进行有意义的投资。我们的数据显示,同时也是公司最高主要高管的蔡东晨持股最多,为24%。当内部人士持有公司大量股票时,投资者认为这是一个积极的信号,因为这表明内部人士愿意将自己的财富绑定在公司的未来中。相比之下,第二和第三大股东持有约6.3%和6.2%的股份。

On further inspection, we found that more than half the company's shares are owned by the top 10 shareholders, suggesting that the interests of the larger shareholders are balanced out to an extent by the smaller ones.

经过进一步检查,我们发现公司一半以上的股份由前十名股东持有,这表明较大股东的利益在一定程度上被较小的股东所平衡。

While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too.

虽然研究公司的机构所有权可以为您的研究增加价值,但研究分析师的建议以更深入地了解股票的预期表现也是一种好做法。有很多分析师在报道该股,因此可能也值得一看他们的预测。

Insider Ownership Of CSPC Pharmaceutical Group

CSPC制药集团的内部所有权

The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.

公司内部人员的定义可能是主观的,并且在不同的司法管辖区之间确实有所不同。我们的数据反映了个人内部人士,至少涵盖了董事会成员。公司管理层经营业务,但首席执行官将对董事会负责,即使他或她是董事会成员。

Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.

当内部所有权表明领导层像公司的真正所有者一样思考时,内部所有权是积极的。但是,高度的内部所有权也可以赋予公司内部的一小部分人巨大的权力。在某些情况下,这可能是负面的。

Our information suggests that insiders maintain a significant holding in CSPC Pharmaceutical Group Limited. It is very interesting to see that insiders have a meaningful HK$19b stake in this HK$80b business. Most would say this shows a good degree of alignment with shareholders, especially in a company of this size. You can click here to see if those insiders have been buying or selling.

我们的信息表明,内部人士持有CSPC制药集团有限公司的大量股份。有趣的是,内部人士在这项800亿港元的业务中拥有190亿港元的大量股份。大多数人会说,这表明了与股东的良好一致性,尤其是在如此规模的公司中。你可以点击这里查看这些内部人士是否在买入或卖出。

General Public Ownership

一般公有制

With a 39% ownership, the general public, mostly comprising of individual investors, have some degree of sway over CSPC Pharmaceutical Group. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.

CSPC制药集团拥有39%的所有权,主要由个人投资者组成的公众对CSPC制药集团有一定程度的影响力。尽管这种所有权规模可能不足以影响对他们有利的政策决定,但它们仍然可以对公司政策产生集体影响。

Private Company Ownership

私人公司所有权

We can see that Private Companies own 6.4%, of the shares on issue. Private companies may be related parties. Sometimes insiders have an interest in a public company through a holding in a private company, rather than in their own capacity as an individual. While it's hard to draw any broad stroke conclusions, it is worth noting as an area for further research.

我们可以看到,私人公司拥有已发行股份的6.4%。私营公司可能是关联方。有时,内部人士通过控股私营公司而对上市公司拥有权益,而不是以个人身份拥有权益。尽管很难得出任何宽泛的结论,但值得注意的是,这是一个需要进一步研究的领域。

Next Steps:

后续步骤:

While it is well worth considering the different groups that own a company, there are other factors that are even more important. For instance, we've identified 1 warning sign for CSPC Pharmaceutical Group that you should be aware of.

尽管值得考虑拥有公司的不同群体,但还有其他因素更为重要。例如,我们已经确定了CSPC制药集团的一个警告信号,你应该注意这一点。

If you would prefer discover what analysts are predicting in terms of future growth, do not miss this free report on analyst forecasts.

如果你想了解分析师对未来增长的预测,千万不要错过这份关于分析师预测的免费报告。

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

注意:本文中的数字是使用过去十二个月的数据计算得出的,这些数据是指截至财务报表日期当月最后一天的12个月期间。这可能与全年年度报告数据不一致。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发